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The effect of aging on human humoral immunity was investigated by studying in vivo the relationship between
influenza specific antibody responses and nonspecific vaccine-induced autoantibody responses in 32 independent,
well-nourished older women volunteers (mean age 86 yr, range 74-97) and 23 young women volunteers (mean age 34
yr, range 23-46). Anti-influenza AITaiwanlll86(HlNl) antibody liters were determined by a hemagglutination
inhibition test (Hi-test), and serum anti-dsDNA antibodies were measured by ELISA prior to, 15, and 30 days after
influenza vaccination. The mean postvaccination fold increase (FI) of the anti-influenza antibody response was
significantly lower in elderly individuals as compared to younger individuals. In contrast, the mean anti-dsDNA
autoantibody level measured 30 days after vaccination was significantly increased in older volunteers as compared to
younger ones. There was a significant negative correlation between the level of the FI of the anti-influenza antibody
response and the anti-dsDNA antibody response (r = - .441, p < .01). Our results suggest that the altered influenza
specific antibody response was associated with an age-related increase in autoimmunity in aging individuals.
THE immunologic theory of aging is based on the hypoth-esis that immunologic changes, including a decline in
specific immunity, may be responsible for the many mani-
festations of the aging process. In addition to the decline in
specific immunity there is an increase in autoimmunity as
demonstrated by the appearance of a variety of autoanti-
bodies in the serum of elderly individuals (1-7).
The incidence of anti-deoxyribonucleic acid (DNA), anti-
cardiolipin, anti-thyroid, anti-thyroglobulin, anti-immuno-
globulins antibodies, rheumatoid factor, and antibodies to
smooth muscle, mitochondria, and gastric parietal cells has
all been shown to increase with age (1,3,4,6-11). The
presence of these autoantibodies has been reported to be
associated with shortened survival in men and women
(12,13). However, the pathological or physiological signifi-
cance of these autoantibodies in the elderly has not yet been
determined.
Immune senescence appears to contribute to the increased
susceptibility of the elderly to infectious diseases, to the
decreased cell-mediated immunity, and to the limited effec-
tiveness of immunization in this population (14-28). There
is general agreement that influenza vaccine efficacy is lower
in elderly as compared to younger individuals (27-29).
However, in some studies, no difference or a better "re-
sponse" to influenza vaccine in the elderly as compared to
younger control subjects has been noted (27). The basis for
these conflicting observations and interpretations concerning
the relationship between aging and the response to influenza
vaccination remains to be elucidated.
The present study was designed to investigate the relation-
ship between increased autoimmunity and decreased specific
immunity in aging individuals. Specifically, the relationship
following vaccination between specific immunity induced by
influenza vaccine (as determined by the presence of anti-
influenza A/Taiwan/ 1/86[H1N1] antibodies in the serum) and
vaccine-induced nonspecific autoantibody responses (as mea-
sured by serum levels of anti-double stranded DNA[dsDNA]
antibodies) was evaluated. The results suggest that funda-
mental differences exist in the immune regulation of the
specific anti-influenza antibody and nonspecific anti-dsDNA
autoantibody responses in elderly individuals as compared to
younger individuals, after influenza vaccination.
METHODS
Subjects. — Fifty-five healthy women volunteers partici-
pated in this investigation and gave their informed consent.
They included 32 elderly (mean age 86 yr) independent,
well-nourished women, and 23 young women (mean age 34
yr). No participants had taken any medication (including
immunosuppressive drugs) in the week prior to the begin-
ning of the study, and none had been vaccinated for in-
fluenza during the past 11 months. Venous blood samples
were collected prior to, 15, and 30 days after vaccination.
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All subjects received one dose of influenza vaccine (0.5 ml)
containing three types of influenza virus: A/Taiwan/1/
86(H1N1), A/Shanghai/11/87(H3N2), and influenza B
Yamagata/16/88.
The influenza vaccine used was a commercially licensed
inactivated whole virus vaccine (Inflexal Berna) manufac-
tured by the Swiss Serum & Vaccine Institute, Bern, Switz-
erland. The concentration of hemagglutinin for each strain
was 20/|xg/ml.
Serologic methods. — The serum anti-dsDNA antibody
concentration was determined by a highly sensitive enzyme
immunoassay (EL1SA) (Anti(ds)DNA-Diagnostic ELISA
Kit, PROGEN, Readysysteme AG, Switzerland) (30). The
test was standardized with WHO-adjusted human standards.
Sera samples were prepared and stored at - 70° C. Immedi-
ately prior to analysis, they were diluted 1:200 (minimum
dilution) with dilution buffer provided with the kit. The
serum sample concentrations of anti-dsDNA antibodies (|xg/
ml) or the binding activity in terms of anti-dsDNA antibodies
(WHO-IUnits/ml) were calculated using a standard curve.
The positive human standard had been standardized using
two different WHO reference materials: (a) human IgG
subclass proteins (WHO IgG Subcommittee), and (b) first
international standard for anti-dsDNA antibody (coded
Wo80). It was noted that 10 WHO-IUnits/ml = 1 |xg/ml.
Concentrations greater than 50 WHO-IU/ml (5 |xg/ml) were
considered to be strongly positive. The antibodies against
dsDNA or single-stranded DNA(ssDNA) of control sera
samples were quantitated by modified Fair assays as
described (31).
The hemagglutination-inhibition test (HI-Test) was per-
formed with sera inactivated at 56 °C for 40 min immediately
prior to the Hi-test. The sera were treated with cholera
filtrate (Sigma Chemical Co., St Louis, MO) in order to
destroy serum nonspecific hemagglutinin (HA) inhibitors
(32), and absorbed with chicken red blood cells. The HI-
tests were performed in 96-well V-shaped microtrays
(Greiner, ABS, Geneva, Switzerland). A standard method/
procedure has been previously described (32).
Statistical methods. —The geometric mean serum concen-
tration of anti-influenza A/Taiwan/ 1/86(H 1N1 )-HI antibodies
(HI-AB) was calculated. The arithmetic mean for anti-
dsDNA antibodies was determined. The significance of dif-
ferences between the mean serum concentration of the two
types of antibodies in older and younger individuals was
analyzed using Student's /-test. Linear regression analysis
was used to study the relationship between the fold increase
(Fl) of anti-influenza A/Taiwan/1/86(H1N1)-Hl antibody (FI
of HI-AB) response and anti-dsDNA antibody response. The
FI of Hl-AB response was calculated as follows: the highest
titer of serum HI-AB 15 or 30 days after vaccination divided
by the titer of HI-AB prior to vaccination.
RESULTS
Anti-influenza A/Taiwan/J/86(H 1N1) antibody response.
— The nature of the specific in vivo anti-influenza antibody
response was evaluated by determining the serum titers of
anti-influenza A/Taiwan/1/86(H1N1) antibodies using a
hemagglutination inhibition test in which the antibody inhi-
bition activity (HI-AB) was expressed as serum antibody
dilution titers. The anti-viral hemagglutinin (HA) antibody
plays a major role in protection against influenza in relation
to virus neutralization (33-35). The time-course of the
antibody response is shown in Figure 1. Prior to vaccination
the mean serum titer of anti-influenza A/Taiwan/1/
86(H1N1)-HI antibodies (HI-AB) tended to be higher in the
group of older subjects than in the younger group, but the
differences were not statistically significant. Following vac-
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Figure A. Comparison of serum anti-influenza A/Tai wan/1/86(H IN 1)
antibody levels (HI-AB) before and 15 and 30 days after influenza vaccina-
tion, in elderly and young subjects. The bars indicate the geometric mean.
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Figure 2. Comparison of the fold increase (Fl) in the anti-influenza A/
Taiwan/1/86(H1N1) antibody response (Fl of HI-AB) after influenza vacci-
nation in elderly and young subjects. The FI of HI-AB based on the titer of
serum HI-AB at day 15 or 30 after influenza vaccination divided by the titer
of serum HI-AB prior to vaccination. The error bars correspond to the mean
± SEM of FI of HI-AB in older and young groups. The number of subjects
studied is shown in parentheses. The mean FI of HI-AB response in older
individuals was significantly decreased as compared to younger individuals
(p < .04).
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cination in younger subjects there was a significant increase
in the serum HI-AB titers at 15 and 30 days as compared to
the serum titers prior to vaccination {p = .0028 at 15 days, p
= .0064 at 30 days). In contrast, the serum antibody titers in
older subjects were not significantly increased 15 and 30
days after vaccination.
When the geometric mean HI-AB levels of older and
younger individuals were compared, no differences were
observed between the two groups prior to vaccination or 15
and 30 days after vaccination. However, when the results
were expressed in terms of the fold increase (FI) of the HI-
AB response, a measure of the current vaccine-induced
specific humoral immune response, important differences in
the antibody responses between the two age groups were
observed (Figure 2). Specifically, the mean FI in younger
subjects was significantly greater than the mean FI of older
subjects (p = .039). These results demonstrated that older
subjects have a reduced specific immune response to in-
fluenza A/Taiwan/1 /86(H 1N1) antigen as compared to youn-
ger subjects, even though they may have higher initial levels
of serum HI-AB (see Figure 1). In contrast, young individ-
uals had lower initial serum levels of HI-AB which were
significantly increased following vaccination, as expressed
by the FI. Therefore, while the absolute levels of the HI-AB
were not statistically significantly different between the two
groups (Figure 1), the levels of the current specific immune
responses were quite different (Figure 2).
The immune response to influenza vaccine was further
investigated by determining the number of individuals who
did not respond to the vaccination. A "nonresponder" was
defined as an individual with an FI equal to or less than 2.
There were 33% and 9% nonresponders in the older and
younger groups, respectively. Therefore, the capacity of
elderly individuals to respond to the vaccine was decreased,
and a greater number of them were nonresponders.
The antibody responses to influenza A/Shanghai/11/
87(H3N2) and B Yamagata/16/88 were also significantly
decreased in the elderly in terms of the FI as compared to
young controls (data not shown). For the purpose of analyz-
ing the relationship between antigen specific response and
nonspecific autoantibody response following influenza vac-
cination, only the data obtained from one virus strain (A/
Taiwan/1/86[HIN 1]) have been presented. This strain, a
relatively old virus (1986) (as compared to A/Shanghai/11/
87 and B Yamagata/16/88), was isolated from patients in
Switzerland in 1987, 1988, and 1989. Therefore, most
individuals in our study, in both the young and old groups,
may have had specific memory T cells for A/Taiwan/1/
86(H1N1) epitopes. The other two strains (A/Shanghai/11/
87 and B Yamagata/16/88 viruses) appeared in Switzerland
after 1989. This we considered too close to the time (1990)
when we started this investigation.
Serum anti-dsDNA antibodies in elderly and young indi-
viduals. — The serum anti-dsDNA antibody concentration
was determined by a commercially available sensitive stan-
dardized (ELISA) assay. Quantitative analysis could be
performed due to the availability of positive standards with a
defined human antibody concentration. According to the
reference range provided with the kit (Progen, Ready-
Systeme, AG) anti-dsDNA antibody concentrations of 25-
50 WHO-IU/ml (equal to 2.5-5 (xg/ml) were considered to
be weakly positive, whereas antibody concentrations greater
than 50 WHO-IU/ml (5 |xg/ml) were strongly positive. For
the purpose of this study the threshold of positive level was
defined as 30 WHO-IU/ml. This was based on the observa-
tion that more than 95% of normal young women controls
had serum anti-dsDNA antibody levels below this value.
Eleven of 32 (34%) of older individuals had positive serum
anti-dsDNA antibody levels (values greater than 30 WHO-
IU/ml) prior to vaccination (Figure 3) compared to 1 of 23
(4%) of younger individuals. The concentration (mean ± 1
SD) of anti-dsDNA antibodies was significantly increased in
elderly as compared to younger individuals (23.55 ± 11.05
and 12.84 ± 9.0, p < .001), respectively.
Most antibodies defined as reactive with dsDNA recog-
nize the deoxyribose phosphate backbone of the DNA and
are therefore also capable of reacting with ssDNA(36). The
following control sera were used to detect the presence of
cross-reactions of this type and to verify the specificity of the
anti-dsDNA antibody test (kits): (a) Two samples from
patients with rheumatoid arthritis (RA) that were strongly
positive for anti-ssDNA antibodies, negative for anti-
dsDNA antibodies by the Fair assay, and negative for anti-
dsDNA antibodies in the sera (20, 16 WHO-IU/ml) by
dsDNA ELISA-Kit; (b) Two selected sera from patients with
systemic lupus erythematosus that had high levels of anti-
dsDNA antibodies (40, 65% binding activity) but no evi-
dence of ssDNA as demonstrated by the Farr assay also
showed strong positive anti-dsDNA antibodies (> 400, 350
WHO-IU/ml) by the dsDNA ELISA-Kit.
The study of changes in the concentration of serum anti-
dsDNA autoantibodies following vaccination revealed a
significant increase in the level of anti-dsDNA antibody 30
days after vaccination compared with the level before vacci-
nation in both old and young age groups (p < .001 in both)
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Figure 3. Distribution of anti-dsDNA antibodies in elderly and young
individuals. The results are expressed in WHO standard units (WH0-1U/
ml). The bars indicate the mean of anti-dsDNA antibodies in each group.
The number of subjects studied is shown in parentheses. The dashed line
indicates the threshold of positive level, defined as (30 WHO-IU/ml).
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(Table 1). In addition, 30 days after vaccination, the mean
serum level of anti-dsDNA antibodies in the elderly group
was significantly greater (mean ± 1 SD: 52.28 ± 35.04
WHO-IU/ml) than the mean serum concentration of the anti-
dsDNA antibody in the younger group (32.32 ± 16.31
WHO-IU/ml, p < .01). The number of individuals consid-
ered positive for anti-dsDNA antibodies was increased at 30
days after vaccination in both groups (77% in old, 44% in
young). Thus, vaccination with influenza vaccine induced or
enhanced the appearance of anti-dsDNA antibodies in both
groups, but the effect was more pronounced in the older age
group (greater proportion of positive individuals and higher
serum concentrations). The relationship between influenza
vaccine-induced specific antibody responses and influenza
vaccine-induced nonspecific autoantibody responses in
healthy older people was evaluated by linear regression
analysis. There was a significant negative correlation be-
tween the FI of HI-AB and the anti-dsDNA antibody concen-
tration (30 days after vaccination) in elderly (r = - .441, p
< .01) (Figure 4), as well as in the group of all individuals
(elderly and young, n = 53, r = - .360, p = .01). There
was no significant correlation between the levels of anti-
dsDNA antibody prior to vaccination and the titers of HI-AB
15 or 30 days after vaccination (r = - .251, p > . 10 and r
= - . 158, p > . 10) respectively.
Since 66% of the older and 96% of the younger individ-
uals had weakly positive or negative anti-dsDNA antibody
levels (< 30 WHO-IU/ml) prior to vaccination (see Figure
3), it was not possible to study the relationship between the
change in anti-dsDNA antibody levels and change in anti-
influenza antibody levels. Although the dsDNA-ELISA test
employed in this study has a relatively high specificity and
sensitivity, nonspecific binding can not be excluded at the
low antibody level in ELISA.
DISCUSSION
Conflicting results have been previously reviewed con-
cerning the association between old age and the specific
antibody response to influenza vaccine in 17 independent
studies during the period 1968-1988 (27). Some reports
have demonstrated a reduced response in older subjects (26-
29). In contrast, others have found little or no difference or,
on occasion, "better" responses as compared with younger
subjects (27). These differences may be explained in part by
different technical and analytical methods employed in the
various studies. For example, the direct comparison of
absolute serum anti-influenza antibody levels in old and
young groups after vaccination may not take into account the
possibility of an enhanced response in some individuals,
who had been either previously vaccinated against influenza
or exposed to influenza virus antigen in the environment. In
our study, 34% of elderly individuals had detectable levels
of HI-AB prior to vaccination (Hi-test titer 3= 1:8, range 1:8-
512) compared to 26% of younger individuals (range 1:8-
32). The mean serum level of HI-AB before vaccination was
greater in the older age group than in the younger age group.
Prior exposure to influenza viral antigens leading to a
subsequent antibody response may also complicate the eval-
uation of the current antibody response to the vaccine. We,
therefore, evaluated the antibody response in terms of the
Table 1. Serum Levels of Anti-dsDNA Antibodies
in Recently Vaccinated Individuals (WHO-IU/ml)
Subjects
Days After Vaccination
0 30 p-value*
Old
Mean ± SD
Young
Mean ± SD
n = 32
23.55 ± 11.05
n = 23
12.84 ± 9.0
n = 30
52.28 ± 35.04
n = 23
32.32 ± 16.31
< .001
< .001
*Statistical analysis of difference between antibody levels before and
after vaccination by Mest.
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Figure 4. Correlation between the FI of HI-AB and the serum anti-
dsDNA antibodies (30 days after influenza vaccination) in elderly subjects.
fold increase (FI), a parameter which reflects the current
anti-influenza antibody response, instead of using the abso-
lute serum titer of anti-influenza antibody. Although no
significant difference between the quantitative titers of the
serum HI-AB in the older and younger age groups could be
demonstrated at 15 and 30 days after vaccination, we were
able to detect significant differences in the specific antibody
response between elderly women and younger ones.
Postvaccination serum anti-influenza antibodies may orig-
inate from three sources: (a) anti-influenza antibodies from
previous vaccination or infection; (b) specific anti-influenza
antibody responses induced by the current influenza vaccina-
tion; and (c) nonspecific polyclonal stimulation by influenza
virus (vaccine) undergoing antigenic shift and drift. Memory
T helper cells stimulated by influenza virus hemagglutinin
(HA) show a broader pattern of recognition than do anti-
influenza antibodies (37). This could form the basis of a
memory response to a new influenza virus infection.
The proportion of nonresponders to the current influenza
vaccination was greater (33%) in elderly as compared to
younger (9%) women. However, 67% of older individuals
still belong to the responder category. Therefore, influenza
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vaccination is recommended for use in older populations
because it also has been demonstrated to reduce sympto-
matic influenza infection in older people: 84% in the unvac-
cinated compared to 39% in vaccinated individuals (38,39).
Nine percent of younger individuals were classified as
nonresponders. The basis for this is unknown, but may be
related in part to genetic factors, as has been previously
demonstrated for hepatitis B vaccine (40).
In contrast to the decrease in specific immunity, our
results confirm the increase in autoimmunity in healthy
elderly people as demonstrated by the appearance of various
serum autoantibodies including anti-dsDNA antibodies ( 1 -
11,41). Some investigations have shown that as many as
77% of healthy elderly individuals have at least one of the
following serum autoantibodies (anti-ssDNA, anti-dsDNA,
anti-cardiolipin, ANA autoantibodies and RF) (4). In the
current study, 34% of healthy elderly women had a signifi-
cant increase in anti-dsDNA antibody levels before vaccina-
tion as compared to 4% of younger women.
The presence of anti-dsDNA antibodies is highly specific
for SLE (42-45); however, the incidence of SLE is not
increased in the elderly (46). Although the mean level of
serum anti-dsDNA antibodies in elderly subjects was signi-
ficantly higher than in younger controls before and after
vaccination in this study, it was still much lower than the
serum levels of anti-dsDNA antibody measured in two active
SLE patients.
Influenza virus can induce the transient appearance of
anti-dsDNA antibodies (47-50). In general, these transient
rises in autoantibodies after antiviral immunization are not
harmful, whereas in other circumstances viral immunization
may be followed by the appearance of or exacerbation of
autoimmunity (Y.P. Huang and J.P. Michel, manuscript in
preparation).
The mean serum level of anti-dsDNA antibodies was
increased by 2.22 times in the older age group and 2.51
times in the younger age group 30 days after vaccination.
This does not necessarily imply that the effect of influenza
vaccine on inducing anti-dsDNA antibodies was similar in
the two groups. In fact, the capacity of the anti-dsDNA
antibody response was higher in elderly than in younger
individuals, even though the mean serum levels of anti-
dsDNA antibodies in elderly individuals prior to vaccination
were 1.8 times greater than the levels in younger individuals.
This suggests that elderly women had significantly greater
numbers of activated B cells than younger ones, and that a
greater proportion of the B-cell repertoire (including resting
B cells) was committed to the production of anti-dsDNA
antibodies. Following vaccination, the proportional increase
in the number of B cells secreting anti-dsDNA antibodies
was similar in the two groups, but the absolute number of
activated anti-dsDNA antibody-secreting B cells was signifi-
cantly greater in older women.
Finally, there was a significant negative correlation be-
tween influenza vaccine-induced specific antibody responses
and the influenza vaccine-induced or enhanced anti-dsDNA
antibody responses that occurred 30 days after vaccination.
The influenza vaccine-induced specific antibody responses
and nonspecific autoantibody responses occurred simultane-
ously. Some individuals, termed nonresponders, had low
levels of specific antibody but elevated levels of anti-dsDNA
antibody 30 days after vaccination. The data suggest that
both the specific and nonspecific antibody responses share
the same or closely related activated immune response sys-
tems. However, the mechanisms of induction of specific and
nonspecific antibody responses appear to be different. Most
elderly individuals who had impaired specific immunity in
response to influenza vaccine had increased nonspecific
autoantibody responses after vaccination.
In conclusion, the study of the effect of aging on the
humoral immune response revealed that fundamental
changes occur in the immune regulation of specific antibody
and nonspecific autoantibody responses with age. The same
immunogen may induce different responses in the elderly
and in the young. Our results suggest that age-related in-
creases in autoimmunity are associated with altered specific
immune responses in aging individuals. Age-related changes
in immune regulation appear to be an important feature in
immune senescence.
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